ronbo54
02-13-2006, 02:24 PM
For those who don't visit the D2OL forums here is the latest from Adam in case you missed it:
"Greetings everyone,
My first visit to TRI (February 3 – 6) is now in the books, and I wanted to take a few minutes here to update the community on the activities from this weekend. We were able to accomplish a great deal of knowledge transfer from Charles and Wolfgang to myself, which will be very important as we move forward. Of more immediate concern to the science and community of the project, we established a strong set of goals for the coming year that will help to revitalize the project and give us a firm foundation for future improvements.
First and foremost, this project is about finding drugs that can help fight diseases. You all have done a lot of work over the last few years in crunching the candidates and targets that we have given you, and your efforts have whittled the field down to several top conformers. While we need to keep working on the current libraries and targets in order to find all of the promising conformers that we can, we realize that a large percentage of the solution space has already been visited. It is for this reason that our top priority for this quarter is the release of a new target and new candidate libraries. To that end, we have identified a promising Avian Flu target and two large libraries of commercially-available drug candidates. I am currently working on formatting the associated files for use with our software.
While the science of drug discovery is the central focus of the project, contributor statistics provide tangible, up-to-date metrics for users to gauge their activity and the contributions they have made to the search for drug treatments. To make tracking our progress a better, more meaningful experience for you (and us!), we are planning to update the statistics processing code to improve both accuracy and currency. I am working with Sengent to make sure we have access to a stable, up-to-date code base before I begin my development work.
Finally, this transition period in the project’s life cycle provides a good opportunity to step back and look at where we’ve been and where we would like to go in the future. Fairly soon, I will be releasing Vision and Values statements for the project, which will help guide our actions moving forward. These will be living documents, and I encourage you to participate in shaping the project by giving me your thoughts on these topics. Then, later in the year, we plan to publish a review article detailing D2OL’s accomplishments and our place in the historical and current Distributed Computing landscape for computational chemistry. This will serve as the perfect celebratory capstone on the first phase of the project as we turn the page and move forward.
As you can see, we had a busy weekend, and there is a lot of work to do in the coming year. I’m confident, though, that we’ll be able to make important improvements to the project and continue to do good science, and I look forward to working with the talented people at TRI and all of you in our dedicated user communities. Please don’t hesitate to contact me with any questions or concerns.
Thank you,
Adam"
"Greetings everyone,
My first visit to TRI (February 3 – 6) is now in the books, and I wanted to take a few minutes here to update the community on the activities from this weekend. We were able to accomplish a great deal of knowledge transfer from Charles and Wolfgang to myself, which will be very important as we move forward. Of more immediate concern to the science and community of the project, we established a strong set of goals for the coming year that will help to revitalize the project and give us a firm foundation for future improvements.
First and foremost, this project is about finding drugs that can help fight diseases. You all have done a lot of work over the last few years in crunching the candidates and targets that we have given you, and your efforts have whittled the field down to several top conformers. While we need to keep working on the current libraries and targets in order to find all of the promising conformers that we can, we realize that a large percentage of the solution space has already been visited. It is for this reason that our top priority for this quarter is the release of a new target and new candidate libraries. To that end, we have identified a promising Avian Flu target and two large libraries of commercially-available drug candidates. I am currently working on formatting the associated files for use with our software.
While the science of drug discovery is the central focus of the project, contributor statistics provide tangible, up-to-date metrics for users to gauge their activity and the contributions they have made to the search for drug treatments. To make tracking our progress a better, more meaningful experience for you (and us!), we are planning to update the statistics processing code to improve both accuracy and currency. I am working with Sengent to make sure we have access to a stable, up-to-date code base before I begin my development work.
Finally, this transition period in the project’s life cycle provides a good opportunity to step back and look at where we’ve been and where we would like to go in the future. Fairly soon, I will be releasing Vision and Values statements for the project, which will help guide our actions moving forward. These will be living documents, and I encourage you to participate in shaping the project by giving me your thoughts on these topics. Then, later in the year, we plan to publish a review article detailing D2OL’s accomplishments and our place in the historical and current Distributed Computing landscape for computational chemistry. This will serve as the perfect celebratory capstone on the first phase of the project as we turn the page and move forward.
As you can see, we had a busy weekend, and there is a lot of work to do in the coming year. I’m confident, though, that we’ll be able to make important improvements to the project and continue to do good science, and I look forward to working with the talented people at TRI and all of you in our dedicated user communities. Please don’t hesitate to contact me with any questions or concerns.
Thank you,
Adam"